Cosmo Pharmaceuticals N.V (C43) — Cash Flow Reinvestment Rate
Cosmo Pharmaceuticals N.V (C43) has a Cash Flow Reinvestment Rate of 3.04x as of June 2022, reinvesting €19.08 Million (capex €1.11 Million plus investments €17.98 Million) from operating cash flow of €6.28 Million. Explore Cosmo Pharmaceuticals N.V (C43) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cosmo Pharmaceuticals N.V Cash Flow Reinvestment Rate (2016–2024)
Historical reinvestment intensity for Cosmo Pharmaceuticals N.V across 6 annual periods. Also explore balance sheet size of Cosmo Pharmaceuticals N.V for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year capital reinvestment analysis for Cosmo Pharmaceuticals N.V. For live market cap and broader valuation context, see Cosmo Pharmaceuticals N.V market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.79x | €129.11 Million | €162.41 Million | €5.65 Million | ▼ -53.6% |
| 2023 | 1.71x | €57.61 Million | €33.62 Million | €15.31 Million | ▲ +532.7% |
| 2022 | 0.27x | €9.00 Million | €33.23 Million | €7.31 Million | ▼ -72.1% |
| 2021 | 0.97x | €12.22 Million | €12.61 Million | €5.49 Million | ▼ -88.7% |
| 2020 | 8.59x | €111.60 Million | €12.98 Million | €4.12 Million | ▲ +217.9% |
| 2016 | 2.70x | €58.65 Million | €21.69 Million | €18.43 Million | — |